This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Edwin Choy, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01583543
First received: April 18, 2012
Last updated: April 11, 2017
Last verified: April 2017
April 18, 2012
April 11, 2017
May 2012
January 2014   (Final data collection date for primary outcome measure)
Objective Response Rate of Olaparib [ Time Frame: 2 years ]

Number of participants with objective response rate as defined as PR+CR as determined by RECIST vs. 1.1.

Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Objective Response Rate of Olaparib [ Time Frame: 2 years ]
Evaluate the objective response rate of olaparib in adult patients with recurrent and/or metastatic Ewing's sarcoma following failure of conventional chemotherapy
Complete list of historical versions of study NCT01583543 on ClinicalTrials.gov Archive Site
  • Progression-Free Survival [ Time Frame: Two years ]
    Number of patients with progression free survival after two years from starting the trial.
  • Overall Survival [ Time Frame: Two years ]
    Number of patients survived for 2 years after enrolling onto this study.
  • Number of Participants Experiencing a Grade 3 or 4 Clinically Significant and Related Adverse Event [ Time Frame: 2 years ]
    Adverse events were graded according to CTCAE v.4 (Common Terminology Criteria for Adverse Events). Events are graded on a scale of 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = fatal. Only events that are clinically significant and which the treating investigator considers to be related to administration of olaparib are counted for this outcome measure.
  • Progression-Free Survival [ Time Frame: Two years ]
  • Overall Survival [ Time Frame: Two years ]
  • Number of Participants with Adverse Events [ Time Frame: Two years ]
    Participants will be followed during the study for all adverse events as catalogued and graded by CTCAE version #4.
Not Provided
Not Provided
 
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
This research study is a Phase II clinical trial to test the efficacy of Olaparib in adult participants with recurrent/metastatic Ewing's Sarcoma following failure of prior chemotherapy.

Primary Objectives Evaluate the objective response rate of olaparib in adult patients with recurrent and/or metastatic Ewing's sarcoma following failure of conventional chemotherapy.

Secondary Objectives To evaluate the progression-free survival, overall survival, and safety of olaparib in this patient population (ie Number of Participants With Adverse Events). As an exploratory objective, the investigators will evaluate (in subjects who agree to an optional biopsy) differences in pre- and post-treatment tumor DNA alterations and differences in levels of protein and RNA expression related to PARP inhibition.

Study Design Potential subjects who discuss and sign the informed consent form will undergo screening studies. Eligible patients will administer olaparib and obtain restaging imaging studies after 6 and 12 weeks on study, and then every 8 weeks thereafter. Participants will remain on study drug until disease progression, onset of unacceptable toxicities, or subject withdraws consent.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Ewing's Sarcoma
Drug: Olaparib
400mg PO BID Continuous
Other Name: AZD 2281
Experimental: Olaparib
400mg PO BID Continuous
Intervention: Drug: Olaparib
Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GD. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 5;14:813. doi: 10.1186/1471-2407-14-813.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
November 2014
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed Ewing's sarcoma
  • Normal organ and bone marrow function
  • Life expectancy of at least 16 weeks
  • Not pregnant or breastfeeding
  • Willing and able to comply with the protocol for the duration of the study
  • Presence of measurable disease

Exclusion Criteria:

  • Involvement in the planning and/or conduct of ths study
  • Previous enrollment in the present study
  • Participation in another clinical study with an investigational product during the 21 days prior to first dose of study drug
  • Previous exposure to any PARP inhibitor
  • Receiving systemic chemotherapy or radiotherapy within 2 weeks of beginning study treatment
  • Receiving prohibited classes of inhibitors of CYP3A4
  • Persistent clinically significant toxicities caused by previous cancer therapy
  • Known myelodysplastic syndrome or acute myeloid leukemia
  • Symptomatic, uncontrolled brain metastases
  • Major surgery within 14 days of starting study treatment
  • Considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disorder or active, uncontrolled infection
  • Unable to swallow orally administered medication or with gastrointestinal disorders likely to interfere with absorption of the study medication
  • Known to be serologically positive for HIV and receiving antiretroviral therapy
  • Known active Hepatitis B or C
  • Known hypersensitivity to olaparib or any of the excipients of the product
  • Uncontrolled seizures
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01583543
11-470
Yes
Not Provided
Plan to Share IPD: No
Edwin Choy, MD, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Principal Investigator: Edwin Choy, MD PhD Massachusetts General Hospital
Massachusetts General Hospital
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP